Clinical Study

Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy

Table 5

Mean percent of change of main parameters after than before treatment among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).

Parameters Mean percent of change (%) among the studied patients with colorectal cancer receiving chemotherapy ()-test
Group 1
(treated with lactoferrin)
()
Group 2
(not treated with lactoferrin)
()

Serum lactoferrin (LF) (ng/mL):
 Range9.73–414.71↓8.31–9.094.3800.001*
 Mean ± SD111.17 ± 96.691.65 ± 5.36
Serum GST (ng/mg):
 Range9.22–100.20↓0.56–0.716.2210.001*
 Mean ± SD31.83 ± 19.83−0.26 ± 0.41
Interferon gamma (INF-γ) (pg/mL):
 Range1.21–10.62↓2.57–0.739.0270.001*
 Mean ± SD5.12 ± 2.18−0.33 ± 0.84

Note: *significant ().